Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Irinotecan Liposome Injection in Advanced Pancreatic Cancer
NCT04482257Phase 1Unknown
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of irinotecan liposome in pancreatic cancer (PC) (2 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 4 more. Status: unknown.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04482257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482257.